Patients treated with HAART who are obese when anti-HIV treatment is initiated, those who have taken protease inhibitors for longer, and those who have lipodystrophy are at greater risk of developing diabetes mellitus, according to Spanish research published as research correspondence in the April 2003 edition of AIDS.
Investigators in Malaga, Spain conducted a case control study involving 745 HAART patients between 1997 and 2001.
In total 34 cases (4.5% of the patient population) of diabetes mellitus were diagnosed and 71 patients (9.5%) had glucose intolerance. These patients were matched with controls of the same age, weight and sex.
Investigators looked at possible risk factors for diabetes mellitus including a family history of the condition, body mass index when HIV infection was first diagnosed, risk factors for HIV infection, and type and duration of anti-HIV therapy.
In univariate analysis patients with diabetes were found to be more likely to have a family history of diabetes, be obese, and have lipodystrophy. However, multivariate analysis showed that only obesity (BMI> 27.3kg/m2 at the time when anti-HIV therapy was first started, duration of treatment with a protease inhibitor, and lipodystrophy were significant.
The investigators conclude that “our research suggests a multifactorial aetiology of d(iabetes) m(ellitus) in patients with HIV infection” with personal, genetic and HIV-associated factors all playing a role. They recommend that all patients should be checked for risk factors of diabetes before starting HAART and should be regularly reevaluated.
Further information on this website
Daibetes - overview
Body fat changes on HAART (lipodystrophy) - overview
Rosario P et al. Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case controlled study. AIDS 17:933 – 935, 2003.